Alimera Agrees to European Launch of Iluvien
Alimera Sciences Inc. has signed a Master Services Agreement with Quintiles Commercial Europe Ltd. for the commercial launch of Iluvien in certain European countries. Iluvien is Alimera's product for the treatment of chronic diabetic macular edema considered insufficiently responsive to available therapies.
"We believe this strategic collaboration with Quintiles will be pivotal in achieving a successful launch of Iluvien in Europe, and at the outset, our initial launch market of Germany," says Dan Myers, president and chief executive officer of Alimera. "Quintiles' broad track-record in the implementation and execution of multi-country, European commercialization projects made the organization an ideal services provider for Alimera in support of the commercial launch of Iluvien in Europe."
Services provided by Quintiles under the Master Services Agreement may include marketing, brand management, sales promotion and detailing, market access, regulatory, medical science liaison, and communications and advisory services in certain European countries. Under this agreement, Alimera and Quintiles will enter into individual project orders that will specify the services to be provided.
The German Project Order, the first under the Master Services Agreement, was signed Nov. 28. Under this project order, Quintiles Commercial Germany GmbH will provide services related to recruitment, employment, deployment, and administration of the ILUVIEN commercialization team in Germany through Dec. 31, 2015. Alimera and Quintiles expect to sign additional project orders for similar services in the United Kingdom and France. Quintiles began interviewing and hiring personnel in Germany, the United Kingdom, and France in September in anticipation of the execution of project orders in all three countries.
"This relationship leverages Quintiles' core commercial talent and strengths. In addition, as the healthcare landscape has become more complex, it is increasingly important to engage with multiple stakeholders across the patient pathway. We have the broad expertise and experience to make this happen," says Chris Pepler, senior vice president, Commercial Solutions at Quintiles. "As Alimera Sciences enters these critical markets, we are excited to partner with them to help drive the success of Iluvien in the European ophthalmic market."
Release Date: December 4, 2012